CD80/IL-2 expressing autologous whole cell vaccine (King's College London)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD80/IL-2 expressing autologous whole cell vaccine (King's College London)
Drug Alias NameCD28 cotimulator/IL-2 expressing autologous whole cell vaccine (King's College London)
ClassificationCell and gene therapy > Cell therapyVaccines > Application > Therapeutic vaccine
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsInterleukin-2 receptor agonists
TargetsInterleukin-2 receptorT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKing'S College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKing'S College London
Active IndicationsN/A
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A